Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

U.S. supreme court abortion reversal would be global ‘catastrophe’ for women

The probable demise of abortion as a federal right in the US will be a “catastrophe” for women in low and middle-income countries, with an emboldened anti-choice movement likely to raise renewed pressure on hard-won gains, doctors and activists have warned.

The leak this month of the US supreme court’s draft majority opinion, which argued that the 1973 ruling effectively legalising abortion had been “egregiously wrong from the start”, stunned and enraged many in America.

But those shock waves did not stop at the borders of the US, as pro-choice figures around the world – many in countries with restrictive abortion laws and high levels of social stigma around reproductive rights – warned that Justice Samuel Alito’s words would “send a really clear message” of inspiration to anti-choice groups.

Source: The Guardian

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!